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In 1848, Louis Pasteur used tweezers 
to pick apart two types of tartaric 
acid crystals, and thus discovered the 
principle of chirality. Chiral 
compounds (from kheir. the Greek 
for hand) exist as one of two 
enantiomers -compounds with the 
same chemical formula but mirror- 
image structures. 
h’ow, 150 years after Pasteur’s 
discovery, the pharmaceutical 
industry is completing its conversion 
to single-enantiomer drugs. An 
estimated 78% of drugs will be single 
enantiomers by the year 2000. But a 
significant period of modern drug 
discovery has involved the generation 
of enantiomeric mixtures, or 
racemates, and a few companies are 
taking a hard look at those mixtures. 
Enantiomers of drugs often differ in 
their interactions with proteins, which 
after all are made of enantiomeric 
building blocks (I,, not D, amino 
acids). I f  the enantiomers of carvone 
can elicit the distinctive smells of 
either caraway seeds or spearmint, it 
is not surprising that enantiomers of 
drugs differ in their effects. 
Chiroscience Group, plc 
(Cambridge, UK) has identified a 
number of drugs as candidates for 
chiral switches - the selection of one 
enantiomer from a racemate drug 
based on its improved activity or 
reduced side effects relative to the 
mixture. One of those candidates - 
an enantiomer of bupivicaine - has 
just been approved for marketing as a 
local anesthetic. But in the face of 
competition, and in anticipation of the 
limited life of the chiral switch idea. 
Chiroscience has shifted its focus to 
unusual genetic diseases in the hope 
of identifying new drug targets. 
Farming the old 
Chiroscience began as Enzymatics, a 
company that used selective enzyme 
reactions to separate one enantiomer 
from a racemate. As it moved further 
into chiral chemistry, the company 
morphed into Chiroscience and 
identified several candidates for chiral 
switches. A couple of those drugs were 
licensed to other companies, leaving 
only levobupivicaine, an enantiomer 
of bupivicaine that substantially- 
reduces the side effect of heart 
damage caused by the original drug. 
Other companies, notably Sepracor 
Inc. (Marlborough, Massachusetts) 
and Celgene Corp. (Warren, New 
Jersey), have made similar 
discoveries. “Innovators are typically 
moving onto the next new entity, 
rather than investigating how to make 
the existing one better,” says Steve 
Wald, vice president of chemistry 
research and development at Sepracor. 
“We’re applying 90s technology to 
drugs developed in the 70s.” 
Chiroscience is either fast-moving 
and adaptable, or a company that 
can’t settle on a vision. 
Chiral switches are an attractive 
approach co drug discovery. The 
drug’s synthesis and market are 
largely known, and a new patent can 
be issued with full protection of the 
enantiomer as a new chemical entity. 
Sepracor’s chiral switch candidates 
include the (R) enantiomer of the 
bronchodilator albuterol (better 
known as Ventolin or Proventil), 
which reduces the jitteriness and 
cardiac effects of albuterol, and no 
longer worsens asthma with repeated 
use. Sepracor is also investigating Eli 
Lilly’s Prozac. The t R) enantiomer of 
Prozac has better pharmacokinetics 
than the racemate, and the (S’) 
enantiomer shows activity against 
migraines that the racemate lacks. 
Sepracor’s Allegra illustrates 
another way to get around a side 
effect. In this case the side effect was 
cardiac arrhythmia when the allergy 
drug Seldane was combined with 
certain antibiotics or antifungals. 
(When Seldane was developed there 
were no models to detect this type of 
arrhythmia.) Allegra is an active 
metabolite of Seldane that no longer 
shows these interactions. 
A chiral switch is not always the 
solution. The teratogenic effects of 
Celgene’s thalidomide appear to be 
caused by the pharmacologically 
active enantiomer. In any case, 
administering a single enantiomer 
would be pointless, as the two 
enantiomers are interconverted in 
the body 
The new approach: chiral from the start 
Chiral switches are a non-renewable 
resource, because the pharmaceutical 
industry is leaving racemates behind. 
In 199’ the Food and Drug -, 
Administration began demanding 
that single enantiomers be tested in 
trials, if at all possible. A racemate 
drug now requires three sets of 
clinical trials: with the racemate and 
each enantiomer. This has 
encouraged drug companies to 
develop single enantiomer drugs. 
Improved chemistry has made 
that feasible. “Any drug that would be 
introduced today would be 
introduced as a single enantiomer.” 
says Barry Trost (Stanford Iniversity, 
Palo Alto, California). although drugs 
whose enantiomers are interconverted 
in the body are one exception. Based 
on improvements in asymmetric 
chemistry, he says “there is no limit” 
to the number of possible chiral 
centers that can be incorporated into a 
drug. “What limits things is really the 
size of what can be a drug.” 
‘I’hus there is a large demand for 
chiral synthesis and isolation of 
enantiomers. Chiroscience provides 
these services through its subsidiary 
Chirotech l-ethnology Limited. In 
addition to providing contract chiral 
synthesis, Chirotech sells collections 
of chiral building blocks and catalysts. 
Racemates can be resolved 
(separated into their constituent 
enantiomers) if one enantiomer 
preferentially crystallizes, reacts with 
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another chemical, or reacts with an 
enzyme. Chiroscience’s founding 
technology of enzymic resolution 
remains the most common 
technique, but chemicals are more 
often used to racemize the 
undesirable enantiomer so that half 
of the starting material is not lost. 
An effective chiral synthesis 
removes the need for an); resolution 
or rdcemization. “Asymmetric 
catalysis is still in its infancy, so 
people are still using a lot of 
resolution.” says Trost. “But as the 
chemistry gets further along, 
resolution will get shunted to the 
side. That will not happen overnight 
because there are significant cost 
issues in optimizing the reactions.” 
Chirotech has licensed Trost’s 
methods for palladium-catalyzed 
asymmetric allylic substitutions, and 
DuPont’s methods for transition-metal 
catalyzed asymmetric hydrogenation. 
Asymmetric epoxidation is also 
proving an important synthetic tool. 
Thidc bones and T cells 
Sepracor emphasizes that there are 
over 500 drugs currently marketed as 
racemates, and the company’s long 
list of developmental drugs suggests 
that they will be busy for some time. 
But for Chiroscience the list was 
dwindling by 1994. when John 
Padfield, a former executive at Glaxo, 
took over as CEO. 
‘We were well ahead of them,” 
says Wald. “We launched the patent 
groundwork when they were still a 
company that did bioresolution.” 
Chiroscience added projects in 
phosphodiesterases and matrix 
metalloproteinases. but the real leap 
into the unknown was in 1996 when it 
acquired Darwin Molecular 
Corporation (Seattle, Washington). 
The gene-discovery arm of Darwin 
was absorbed into Chiroscience, while 
the pharmacogenomics side became a 
spin-off called Rapigene, Inc. 
Darwin’s genomics and genetics 
was a far cry from chiral synthesis. 
“Chiral chemistry was an excellent 
platform technology to launch a start- 
up, but . . . gene discovery represents 
[a] much greater potential for 
generating innovative projects in the 
future,” says Robert Jackson, the 
head of research and development at 
Chiroscience. Eventually, he says, 
the company aims to become an 
integrated gene-to-drug company 
For now Chiroscience is focusing 
on target discovery through genetics, 
but not just any genetics. “We are 
using mutation as a surrogate for drug 
action,” says Jackson. One example is 
the gene for human sclerosteosis - a 
disease found in a small rural 
population in Southern Africa. 
Problems in bone turnover lead to 
bones that are up to twice as dense as 
normal, a cranium up to an inch thick, 
and eventually death from pressure on 
the brain if patients are not treated. 
So where is this leading? “If we 
inhibit the gene product we should 
make bone more dense and have a 
potential osteoporosis drug,” say 
Jackson. “Unlike cancer or 
atherosclerosis genes where you need 
to unravel what is the real cause, here 
the phenotype is self-validating. We 
know that if we inhibit this gene we 
will make bone denser - the 
phenotype tells us this.” Jackson 
contrasts this approach with the 
brute-force isolation of multiple 
candidate genes by companies like 
Human Gcnome Sciences, Inc. 
(Rockville, Maryland), or the 
complex trait analysis by companies 
like slillennium Pharmaceuticals, 
Inc. (Cambridge, Massachusetts). 
“There will probably be a limited 
number of these [human diseases] so 
we will supplement them with mouse 
genetics.” says Jackson. “Mouse 
genetics is only just starting to gear 
up. This is a place where a small 
company can make a contribution.” 
The mouse mutants that have 
been analyzed, says Jackson, tend to 
be the ones with very obvious 
primary phenotypes. “There has 
been very little work where you have 
to look beyond things like coat color 
and test phenotypic functions like 
bone density and immune function.” 
Chiroscience’s entry point is the 
Scurfy mouse, discovered in Oak 
Ridge, Tennessee, over 30 years ago. 
Affected mice have a spontaneous 
autoimmune disease. and die very 
young when their T cells mount a 
massive attack on all tissues. 
Chiroscience has isolated the relevant 
gene (although, as with the 
sclerosteosis gene, the identity of the 
gene has not been disclosed), and 
found that it controls a pathway that 
inhibits T cell proliferation. A drug 
that inhibits this pathway should act as 
an immunostimulant for those with 
HI\‘, especially as the CD4 population 
of ‘I’ cells is specifically affected. 
The pharmacogenomics offshoot 
Rapigene’s basic technology involves 
a series of oligonucleotides tagged 
with small molecules. The 
oligonucleotides stick to mRNA made 
by active genes, the tags are removed 
by shining light on the photocleavable 
linkers, and the tags are then detected 
by a mass spectrometer. With this 
process, Rapigene can detect the 
expression levels of up to 100 genes 
by analyzing a single well of a 96-well 
plate. “The beauty of the mass-spec 
tag is you can use a huge number of 
them - hundreds as compared to just 
a few fluorescent tags,” says Jackson. 
“We see this as an alternative to 
Affymetrix-type chips.” 
The expression analysis should 
allow more accurate subdivisions of 
patient populations so that a positive 
outcome (or a side effect) in a 
particular minority can be detected. 
Rapigcne’s tags should be 
particularly useful in small trials, says 
Jackson, because “our technology 
can be reprogrammed at will.” 
Even as Chiroscience enters the 
brave new world of 
pharmacogenomics, Sepracor 
remains happy with its approach of 
updating imperfect drugs. “I don’t 
think this is just a short-term 
strategy ” says Wald. “In 2010 we are 
going to know something more about 
drugs and how to make them better.” 
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